Immune dysregulation in chronic inflammatory demyelinating polyneuropathy

被引:0
作者
Li, Yingkai [1 ]
Yi, John S. [2 ]
Guptill, Jeffrey T. [1 ]
Juel, Vern C. [1 ]
Hobson-Webb, Lisa [1 ]
Raja, Shruti M. [1 ]
Karatz, Tabitha [1 ]
Gable, Karissa L. [1 ,3 ]
机构
[1] Duke Univ, Med Ctr, Dept Neurol, Neuromuscular Div, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Surg, Div Surg Sci, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, DUMC Box 3909, Durham, NC 27710 USA
基金
美国国家卫生研究院;
关键词
CIDP; Immune dysregulation; Innate immune cells; T cells; B cells; REGULATORY T-CELLS; AUTOIMMUNE NEUROPATHY; OUTCOME MEASURES; POLYRADICULONEUROPATHY; TOLERANCE; RESPONSES;
D O I
10.1016/j.jneuroim.2024.578360
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disorder of the peripheral nerves with an incompletely understood underlying pathophysiology. This investigation focused on defining B and T cell frequencies, T cell functional capacity and innate immune system analysis in patients with CIDP. Methods: By using multi-parameter flow cytometry, we examined the phenotype and function of PBMCs in 25 CIDP patients who were relatively clinically stable on treatment who met EFNS/PNS criteria, 21 patients with genetically confirmed hereditary neuropathy and 25 healthy controls. We also evaluated the regulatory T cell (Treg) inhibitory capacity by co-culturing Treg and effector T cells. Results: Proinflammatory CD4 T cells, especially type 1 helper T cell (Th1) and CD8 T cells in patients with CIDP were found to have an enhanced capacity to produce inflammatory cytokines. There was no difference in frequency of Th17 regulatory cells in CIDP patients versus healthy controls, however, Treg function was impaired in CIDP patients. There was no remarkable difference in innate immune system measures. Within B cell subsets, transitional cell frequency was decreased in CIDP patients. Interpretation: Patients with CIDP clinically stable on treatment continued to show evidence of a proinflammatory state with impaired Treg function. This potentially implies an inadequate suppression of ongoing inflammation not addressed by standard of care therapies as well as persistent activity of disease while on treatment. Targeting T cells, especially inhibiting Th1 and polyfunctional CD8 T cells or improving Treg cell function could be potential targets for future therapeutic research.
引用
收藏
页数:8
相关论文
共 29 条
  • [1] CD19 as a therapeutic target in a spontaneous autoimmune polyneuropathy
    Abraham, P. M.
    Quan, S. H.
    Dukala, D.
    Soliven, B.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 175 (02) : 181 - 191
  • [2] Treatment of chronic inflammatory demyelinating polyneuropathy
    Allen, Jeffrey A.
    Lewis, Richard A.
    [J]. MUSCLE & NERVE, 2022, 66 (05) : 552 - 557
  • [3] Monitoring Clinical Course and Treatment Response in Chronic Inflammatory Demyelinating Polyneuropathy During Routine Care A Review of Clinical and Laboratory Assessment Measures
    Allen, Jeffrey A.
    Merkies, Ingemar S. J.
    Lewis, Richard A.
    [J]. JAMA NEUROLOGY, 2020, 77 (09) : 1159 - 1166
  • [4] CIDP diagnostic pitfalls and perception of treatment benefit
    Allen, Jeffrey A.
    Lewis, Richard A.
    [J]. NEUROLOGY, 2015, 85 (06) : 498 - 504
  • [5] Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice
    Bour-Jordan, W
    Thompson, HL
    Bluestone, JA
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 175 (09) : 5649 - 5655
  • [6] INTERNATIONAL CLINIMETRIC EVALUATION OF THE MG-QOL15, RESULTING IN SLIGHT REVISION AND SUBSEQUENT VALIDATION OF THE MG-QOL15R
    Burns, Ted M.
    Sadjadi, Reza
    Utsugisawa, Kimiaki
    Gwathmey, Kelly G.
    Joshi, Amruta
    Jones, Sarah
    Bril, Vera
    Barnett, Carolina
    Guptill, Jeffrey T.
    Sanders, Donald B.
    Hobson-Webb, Lisa
    Juel, Vern C.
    Massey, Janice
    Gable, Karissa L.
    Silvestri, Nicholas J.
    Wolfe, Gil
    Cutter, Gary
    Nagane, Yuriko
    Murai, Hiroyuki
    Masuda, Masayuki
    Farrugia, Maria Elena
    Carmichael, Caroline
    Birnbaum, Simone
    Hogrel, Jean-Yves
    Nafissi, Shahriar
    Fatehi, Farzad
    Ou, Changyi
    Liu, Weibin
    Conaway, Mark
    [J]. MUSCLE & NERVE, 2016, 54 (06) : 1015 - 1022
  • [7] Impairment of circulating CD4+CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy
    Chi, Li-Jun
    Wang, Hua-Bing
    Wang, Wei-Zhi
    [J]. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2008, 13 (01) : 54 - 63
  • [8] The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells
    Ivanov, Ivaylo I.
    McKenzie, Brent S.
    Zhou, Liang
    Tadokoro, Carlos E.
    Lepelley, Alice
    Lafaille, Juan J.
    Cua, Daniel J.
    Littman, Dan R.
    [J]. CELL, 2006, 126 (06) : 1121 - 1133
  • [9] The role of macrophages in immune-mediated damage to the peripheral nervous system
    Kiefer, R
    Kieseier, BC
    Stoll, G
    Hartung, HP
    [J]. PROGRESS IN NEUROBIOLOGY, 2001, 64 (02) : 109 - 127
  • [10] Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients
    Li, Yingkai
    Guptill, Jeffrey T.
    Russo, Melissa A.
    Massey, Janice M.
    Juel, Vern C.
    Hobson-Webb, Lisa D.
    Howard, James F.
    Chopra, Manisha
    Liu, Weibin
    Yi, John S.
    [J]. EXPERIMENTAL NEUROLOGY, 2019, 312 : 43 - 50